With the advent of SGLT2 receptor blockers as a treatment modality for type 2 diabetes, is there any evidence or data regarding use in patients with type 1 diabetes mellitus?—NATHAN GARDNER, PA-C, CPAAPA, Castleton, N.Y.

As it currently stands, SGLT2 receptor blockers are FDA-approved for glycemic control in adults with type 2 diabetes in conjunction with diet and exercise, but the FDA has stated that they are not approved for use in patients with type 1 diabetes, patients with diabetic ketoacidosis, or those with severe renal function.—ABIMBOLA FARINDE, PhD, PharmD, is a professor at Columbia Southern University in Orange Beach, Ala. (203-2) 



These are letters from practitioners around the country who want to share their clinical problems and successes, observations and pearls with their colleagues. We invite you to participate. If you have a clinical pearl, submit it here.